Literature DB >> 21044127

Cytokine levels in serious cardiopathy of Chagas disease after in vitro stimulation with recombinant antigens from Trypanosoma cruzi.

V M B Lorena1, I M B Lorena, S C M Braz, A S Melo, M F A D Melo, M G A C Melo, E D Silva, A G P Ferreira, C N L Morais, V M A Costa, R Correa-Oliveira, Y M Gomes.   

Abstract

The clinical manifestations of human Chagas disease are associated with distinct and complex host-parasite interactions that directly involve the host's immune system. In this study, we analysed the relationship between the production of intracytoplasmic cytokines after in vitro stimulation with the recombinant antigens CRA (cytoplasmatic repetitive antigen) or FRA (flagellar repetitive antigen) from Trypanosoma cruzi and the chronic cardiac or indeterminate clinical forms of Chagas disease. The chagasic patient groups consisted of 39 individuals, selected at the Chagas Disease Unit of the Oswaldo Cruz University Hospital, whom presented either a cardiac form without cardiac dilatation (CARD 1), cardiac form with cardiac dilatation (CARD 2) or indeterminate form (IND). Blood samples were obtained from these patients and cultured in the presence of CRA or FRA. The cytokines produced by lymphocytes and monocytes after antigen stimulation were analysed by flow cytometry. Our results showed that the IFN-γ and TNF-α, produced by CD8+ T lymphocytes after in vitro stimulation with CRA, differed among chagasic patients with CARD 1, CARD 2 or IND. We propose that these cytokines could be utilized as immunological markers for clinical cardiac forms of Chagas disease. In a prospective study of patients presenting IND and CARD 1, the assay performed in this paper could serve as a tool to monitor therapeutic interventions, thus improving the patient's quality of life.
© 2010 The Authors. Scandinavian Journal of Immunology © 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044127     DOI: 10.1111/j.1365-3083.2010.02462.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  14 in total

Review 1.  Advances and challenges towards a vaccine against Chagas disease.

Authors:  Israel Quijano-Hernandez; Eric Dumonteil
Journal:  Hum Vaccin       Date:  2011-11-01

2.  Evaluation of the immune response against Trypanosoma cruzi cytosolic tryparedoxin peroxidase in human natural infection.

Authors:  Magalí C Girard; Gonzalo R Acevedo; Lucía López; Micaela S Ossowski; María D Piñeyro; Juan P Grosso; Marisa Fernandez; Yolanda Hernández Vasquez; Carlos Robello; Karina A Gómez
Journal:  Immunology       Date:  2018-08-03       Impact factor: 7.397

3.  T-Cell Immunophenotyping and Cytokine Production Analysis in Patients with Chagas Disease 4 Years after Benznidazole Treatment.

Authors:  Mauricio Llaguno; Marcos Vinicius da Silva; Lara Rocha Batista; Djalma Alexandre Alves da Silva; Rodrigo Cunha de Sousa; Luiz Antonio Pertili Rodrigues de Resende; Valdo Jose Dias da Silva; Eliane Lages-Silva; Carlo José Freire Oliveira; Juliana Reis Machado; Denise Bertulucci Rocha Rodrigues; Dalmo Correia; Virmondes Rodrigues
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

Review 4.  Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects.

Authors:  Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan; Michael J Heffernan; Kathryn Jones; Jesus G Valenzuela; Shaden Kamhawi; Jaime Ortega; Samuel Ponce de Leon Rosales; Bruce Y Lee; Kristina M Bacon; Bernhard Fleischer; B T Slingsby; Miguel Betancourt Cravioto; Roberto Tapia-Conyer
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

5.  Increase in the expression of CD4 + CD25+ lymphocytic T cells in the indeterminate clinical form of human Chagas disease after stimulation with recombinant antigens of Trypanosoma cruzi.

Authors:  Suellen Carvalho de Moura Braz; Adriene Siqueira de Melo; Maria da Glória Aureliano de Melo Cavalcanti; Sílvia Marinho Martins; Wilson de Oliveira; Edimilson Domingos da Silva; Antonio Gomes Pinto Ferreira; Virginia Maria Barros de Lorena; Yara de Miranda Gomes
Journal:  J Clin Immunol       Date:  2014-09-10       Impact factor: 8.317

6.  The repetitive cytoskeletal protein H49 of Trypanosoma cruzi is a calpain-like protein located at the flagellum attachment zone.

Authors:  Alexandra Galetović; Renata T Souza; Marcia R M Santos; Esteban M Cordero; Izabela M D Bastos; Jaime M Santana; Jeronimo C Ruiz; Fabio M Lima; Marjorie M Marini; Renato A Mortara; José Franco da Silveira
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

Review 7.  Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease.

Authors:  María Cecilia Albareda; Susana Adriana Laucella
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-05       Impact factor: 2.743

8.  Presence of antigen-experienced T cells with low grade of differentiation and proliferative potential in chronic Chagas disease myocarditis.

Authors:  Rafael J Argüello; Carlos Vigliano; Patricia Cabeza-Meckert; Rodolfo Viotti; Fernando Garelli; Liliana E Favaloro; Roberto R Favaloro; Rubén Laguens; Susana A Laucella
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

9.  Elevated serum levels of macrophage migration inhibitory factor are associated with progressive chronic cardiomyopathy in patients with Chagas disease.

Authors:  Romina A Cutrullis; Patricia B Petray; Edgardo Schapachnik; Rubén Sánchez; Miriam Postan; Mariela N González; Valentina Martín; Ricardo S Corral
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

10.  Immunopathological aspects of experimental Trypanosoma cruzi reinfections.

Authors:  Juliana Reis Machado; Marcos Vinícius Silva; Diego Costa Borges; Crislaine Aparecida da Silva; Luis Eduardo Ramirez; Marlene Antônia dos Reis; Lúcio Roberto Castellano; Virmondes Rodrigues; Denise Bertulucci Rocha Rodrigues
Journal:  Biomed Res Int       Date:  2014-06-24       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.